Evidence map›Paper›PMID 38635755›Full record

ArticlePloS one2024

Tuberculosis patients face high treatment support costs in Colombia, 2021.

Oscar Andrés Cruz Martínez, Ingrid García, Gloria Mercedes Puerto, Nelson J Alvis-Zakzuk, Martha Patricia López, Juan Carlos Moreno Cubides, Ángela María Sánchez Salazar, Julián Trujillo Trujillo, Claudia Marcela Castro-Osorio, Vivian Vanessa Rubio and 4 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Oscar Andrés Cruz MartínezPrograma Nacional para el Control de la Tuberculosis, Ministerio de Salud y Protección Social, Bogotá, D.C., Colombia.
Ingrid GarcíaÁrea Prevención y Control de Enfermedades CDE, Organización Panamericana de la Salud/Organización Mundial de la Salud, Bogotá, D.C., Colombia.
Gloria Mercedes PuertoInstituto Nacional de Salud, Red Nacional de Investigación, Innovación y Gestión del Conocimiento de TB en Colombia, Grupo de Micobacterias, Dirección de Investigación en Salud Pública, Bogotá, D.C., Colombia.
Nelson J Alvis-ZakzukGlobal TB Programme, World Health Organization, Geneva, Switzerland.ORCID 0000-0001-9382-214X
Martha Patricia LópezÁrea Prevención y Control de Enfermedades CDE, Organización Panamericana de la Salud/Organización Mundial de la Salud, Bogotá, D.C., Colombia.ORCID 0000-0002-8797-5243
Juan Carlos Moreno CubidesÁrea Prevención y Control de Enfermedades CDE, Organización Panamericana de la Salud/Organización Mundial de la Salud, Bogotá, D.C., Colombia.
Ángela María Sánchez SalazarDirección de Epidemiologia y Demografía, Ministerio de Salud y Protección Social, Bogotá, D.C., Colombia.
Julián Trujillo TrujilloGrupo Emergentes Reemergentes y Desatendidas, Ministerio de Salud y Protección Social, Bogotá, D.C., Colombia.ORCID 0000-0003-0739-5781
Claudia Marcela Castro-OsorioInstituto Nacional de Salud, Red Nacional de Investigación, Innovación y Gestión del Conocimiento de TB en Colombia, Grupo de Micobacterias, Dirección de Investigación en Salud Pública, Bogotá, D.C., Colombia.
Vivian Vanessa RubioInstituto Nacional de Salud, Red Nacional de Investigación, Innovación y Gestión del Conocimiento de TB en Colombia, Grupo de Micobacterias, Dirección de Investigación en Salud Pública, Bogotá, D.C., Colombia.
Carlos Castañeda-OrjuelaInstituto Nacional de Salud, Observatorio Nacional de Salud, Bogotá, D.C., Colombia.
Ernesto MontoroDepartamento CDE, Unidad de VIH, Hepatitis, Tuberculosis e ITS, Organización Panamericana de la Salud/Organización Mundial, Washington, DC, Estados Unidos de América.
Peter NguhiuGlobal TB Programme, World Health Organization, Geneva, Switzerland.
Inés García BaenaGlobal TB Programme, World Health Organization, Geneva, Switzerland.

Funding

World Health Organization 001
6 · The paper itself

Abstract

objectiveTo estimate the baseline to measure one of the three indicators of the World Health Organization (WHO) End TB strategy (2015-2035), measure the costs incurred by patients affected by tuberculosis (TB) during a treatment episode and estimate the proportion of households facing catastrophic costs (CC) and associated risk factors, in Colombia, 2021. MATERIAL AND

methodsA nationally representative cross-sectional survey was conducted among participants on TB treatment in Colombia, using telephone interviews due to the exceptional context of the COVID-19 pandemic. The survey collected household costs (direct [medical and non-medical out-of-pocket expenses] and indirect) over an episode of TB, loss of time, coping measures, self-reported income, and asset ownership. Total costs were expressed as a proportion of annual household income and analyzed for risk factors of CC (defined as costs above 20% annual household income).

resultsThe proportion of TB-affected households incurring in costs above 20% annual household income (CC) was 51.7% (95%CI: 45.4-58.0) overall, 51.3% (95%CI: 44.9-57.7) among patients with drug-sensitive (DS) TB, and 65.0% (95%CI: 48.0-82.0) among drug-resistant (DR). The average patient cost of a TB case in Colombia was $1,218 (95%CI 1,106-1,330) including $860.9 (95%CI 776.1-945.7) for non-medical costs, $339 (95%CI 257-421) for the indirect costs, and $18.1 (95%CI 11.9-24.4) for the medical costs. The factors that influenced the probability of facing CC were income quintile, job loss, DR-TB patient, and TB type.

conclusionMain cost drivers for CC were non-medical out-of-pocket expenses and income loss (indirect costs). Current social protection programs ought to be expanded to mitigate the proportion of TB-affected households facing CC in Colombia, especially those with lower income levels.

Indexed as

PandemicsTuberculosisColombiaCross-Sectional StudiesHealth Care CostsHumansIncome

Identifiers

PMID38635755
PMCPMC11025946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.